Amylin inhibits ovariectomy-induced bone loss in rats
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Amylin (AMY), a peptide co-secreted with insulin by pancreatic beta-cells, inhibits bone resorption and stimulates osteoblastic activity. The ovariectomized (OVX) rat is an established animal model for human osteoporosis. Thus, the present experiment was performed to study the effects of AMY on estrogen deficiency-induced bone loss in rats. Thirty-one 6-month-old Wistar rats were randomized by body weight (BW) into two groups. The first underwent surgical OVX (n=21). The second was sham-operated (SH; n=10). Sixty days after surgery, 11 OVX rats were s.c. injected with rat AMY (3 microg/100 g BW/day, for 30 days; OVX+AMY), and 10 with solvent alone in the same way (0.15 ml/100 g BW; OVX). Each rat, housed in an individual cage, was fed daily the mean quantity of diet consumed the day before by SH rats. This diet contained 0.24% calcium and 0. 16% phosphorus. The 31 animals were killed on day 90. No difference in daily weight gain and BW was observed between groups. Neither AMY treatment nor OVX had any significant effect upon femoral morphology, femoral failure load, diaphyseal femoral density (representative of cortical bone) and total femoral calcium content. Nevertheless, both distal metaphyseal (representative of cancellous bone) and total femoral bone densities were higher in SH and OVX+AMY than in OVX rats. The highest plasma osteocalcin concentration was measured in OVX+AMY rats. Simultaneously, urinary deoxypyridinoline excretion was lower in OVX+AMY than in OVX rats. These results indicate that in OVX rats, AMY treatment inhibited trabecular bone loss both by inhibiting resorption and by stimulating osteoblastic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this experimental model, amylin reduced urinary excretion of deoxypyridinoline and reduced trabecular bone loss, whereas it had no effect on cortical bone indices (101).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [101]
Citations
Cites
Biochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
The ovariectomized rat model of postmenopausal bone loss
Kalu, D. N. (1991) · Bone and Mineral · doi:10.1016/0169-6009(91)90124-i · Cited by 1,361
Cooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8628 · Cited by 1,299
Trends in Endocrinology and Metabolism 1998
Brines, R. (1998) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(98)00013-7 · Cited by 699
Christopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.235 · Cited by 486 · cited 1×
“Their pharmacology has recently been shown to be produced by the co-expression of calcitonin C1a receptors and receptor activity modulating protein (RAMP1) (Muff et al. 1995, Christopoulos et al. 1999 ) in a manner similar to the formation of CGRP receptor from calcitonin receptor-related receptor and RAMP1 (MacLatchi…”
ResultCytokines and Estrogen in Bone: Anti-Osteoporotic Effects
Horowitz, M. C. (1993) · Science · doi:10.1126/science.8480174 · Cited by 453 · cited 1×
“The loss of estrogen at menopause creates an imbalance of osteoblastic and osteoclastic activities such that bone resorption outpaces bone formation (Dempster & Lindsay 1993, Horowitz 1993 ) leading to high turnover bone loss, post-menopausal osteoporosis and increased risk of fractures.”
BackgroundAvian osteoclasts as estrogen target cells.
Oursler, M. J., Osdoby, P., Pyfferoen, J., Riggs, B. L., & Spelsberg, T. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6613 · Cited by 395 · cited 1×
“Osteoclasts contain estrogen receptors and respond to estrogen in vitro by decreasing resorptive activity ( Oursler et al. 1991, 1994 ) and blocking the production of proinflammatory cytokines by bone marrow and bone cells (Pacifici 1998).”
BackgroundDempster, D., Lindsay, R., Dempster, & Lindsay (1993) · The Lancet · doi:10.1016/0140-6736(93)90570-7 · Cited by 356 · cited 1×
“The loss of estrogen at menopause creates an imbalance of osteoblastic and osteoclastic activities such that bone resorption outpaces bone formation ( Dempster & Lindsay 1993, Horowitz 1993) leading to high turnover bone loss, post-menopausal osteoporosis and increased risk of fractures.”
BackgroundBone Density in Non-Insulin-Dependent Diabetes Mellitus: The Rotterdam Study
van Daele, P. L. A., Stolk, R. P., Burger, H., Algra, D., Grobbee, D. E., Hofman, A., Birkenhager, J. C., & Pols, H. A. P. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-6-199503150-00002 · Cited by 308
Cited by
Relationships between fat and bone
Reid, I. R. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0492-z · Cited by 475
“Its systemic administration substantially increases bone volume in mice [67] and rats [ 68 , 69], and the amylin knockout mouse has reduced bone density [70].”
BackgroundAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Type 2 diabetes and the skeleton: new insights into sweet bones
Shanbhogue, V. V., Mitchell, D. M., Rosen, C. J., & Bouxsein, M. L. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00283-1 · Cited by 237
The Impact of Diabetes and Diabetes Medications on Bone Health
Gilbert, M. P., & Pratley, R. E. (2015) · Endocrine Reviews · doi:10.1210/er.2012-1042 · Cited by 209
“ficiency has been shown to lead to bone loss in mice, and treatment with amylin can partially reverse osteopenia in ovariectomized rats (127, 128).”
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
“In this experimental model, amylin reduced urinary excretion of deoxypyridinoline and reduced trabecular bone loss, whereas it had no effect on cortical bone indices (101).”
Background
Metadata
- Authors
- Horcajada-Molteni, M., Davicco, M., Lebecque, P., Coxam, V, Young, A., & Barlet, J.
- Affiliations
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- ORCID
- Coxam, V
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2000-06-01
- Volume
- 165
- Issue
- 3
- Pages
- 663-668
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2158977547
- Cited by
- 40
- References
- 34
- Citations by year
- 2026: 1 · 2020: 4 · 2019: 2 · 2018: 3 · 2016: 1 · 2015: 5 · 2014: 1 · 2012: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Medicinal Plant Pharmacodynamics Research
- Keywords
- amylin, ovariectomy, bone loss, osteoporosis, estrogen deficiency, bone resorption, osteoblast activity, trabecular bone, bone mineral density, osteocalcin, deoxypyridinoline, femur, bone formation markers
- MeSH terms
- Amino Acids, Amyloid, Animals, Calcium, Disease Models, Animal, Female, Femur, Humans, Ovariectomy, Stress, Mechanical, Osteoporosis, Postmenopausal, Osteocalcin, Rats, Wistar, Rats, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amylin inhibits ovariectomy-induced bone loss in rats. https://app.cochat.ai/papers/10.1677/joe.0.1650663
- The paper
- Horcajada-Molteni, M., Davicco, M., Lebecque, P., Coxam, V, Young, A., & Barlet, J. (2000). Amylin inhibits ovariectomy-induced bone loss in rats. Journal of Endocrinology. https://doi.org/10.1677/joe.0.1650663
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.